Literature DB >> 23125332

Relationship between orbital optic nerve axon counts and retinal nerve fiber layer thickness measured by spectral domain optical coherence tomography.

Grant A Cull1, Juan Reynaud, Lin Wang, George A Cioffi, Claude F Burgoyne, Brad Fortune.   

Abstract

PURPOSE: We determined the relationship between total optic nerve axon counts and peripapillary retinal nerve fiber layer thickness (RNFLT) measured in vivo by spectral domain optical coherence tomography (SDOCT).
METHODS: A total of 22 rhesus macaques had three or more baseline measurements in both eyes of peripapillary RNFLT made by SDOCT. Laser photocoagulation then was applied to the trabecular meshwork of one eye to induce chronic unilateral IOP elevation. SDOCT measurements of RNFLT continued approximately every two weeks until the predefined study endpoint was reached in each animal. At endpoint, animals were sacrificed and the optic nerve was sampled approximately 2 mm behind the globe to obtain thin sections for histologic processing and automated axon counting across 100% of the optic nerve cross-sectional area.
RESULTS: At the final imaging session, the average loss of RNFLT was 20 ± 21%, ranging from essentially no loss to nearly 65% loss. Total optic nerve axon count in control eyes ranged from 812,478 to 1,280,474. The absolute number of optic nerve axons was related linearly to RNFLT (axon count = 12,336 × RNFLT((μm)) - 257,050, R(2) = 0.65, P < 0.0001), with a Pearson correlation coefficient of 0.81. There also was a strong linear relationship between relative optic nerve axon loss (glaucomatous-to-control eye) and relative RNFLT at the final imaging session, with a slope close to unity but a significantly negative intercept (relative axon loss((%)) = 1.05 × relative RNFLT loss((%)) - 14.4%, R(2) = 0.75, P < 0.0001). The negative intercept was robust to variations of fitted model because relative axon loss was -14% on average for all experimental glaucoma (EG) eyes within 6% (measurement noise) of zero relative loss.
CONCLUSIONS: There is a strong linear relationship between total optic nerve axon count and RNFLT measured in vivo by SDOCT. However, substantial loss of optic nerve axons (∼10%-15%) exists before any loss of RNFLT manifests and this discrepancy persists systematically throughout a wide range of damage.

Entities:  

Mesh:

Year:  2012        PMID: 23125332      PMCID: PMC3506054          DOI: 10.1167/iovs.12-10752

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  43 in total

1.  Diagnostic capability of optical coherence tomography in evaluating the degree of glaucomatous retinal nerve fiber damage.

Authors:  Ramanjit Sihota; Parul Sony; Viney Gupta; Tanuj Dada; Rajvir Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 2.  Axon degeneration mechanisms: commonality amid diversity.

Authors:  Michael Coleman
Journal:  Nat Rev Neurosci       Date:  2005-11       Impact factor: 34.870

3.  3-D histomorphometry of the normal and early glaucomatous monkey optic nerve head: prelaminar neural tissues and cupping.

Authors:  Hongli Yang; J Crawford Downs; Anthony Bellezza; Hilary Thompson; Claude F Burgoyne
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

Review 4.  A framework for comparing structural and functional measures of glaucomatous damage.

Authors:  Donald C Hood; Randy H Kardon
Journal:  Prog Retin Eye Res       Date:  2007-08-21       Impact factor: 21.198

5.  Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes.

Authors:  Joel S Schuman; Tamar Pedut-Kloizman; Helena Pakter; Nan Wang; Viviane Guedes; Lina Huang; Liselotte Pieroth; Wayne Scott; Michael R Hee; James G Fujimoto; Hiroshi Ishikawa; Richard A Bilonick; Larry Kagemann; Gadi Wollstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

6.  Peripapillary nerve fiber layer thickness measured by optical coherence tomography in patients with no light perception from long-standing nonglaucomatous optic neuropathies.

Authors:  Carmen K M Chan; Neil R Miller
Journal:  J Neuroophthalmol       Date:  2007-09       Impact factor: 3.042

7.  Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma.

Authors:  Keith R G Martin; Harry A Quigley; Danielle Valenta; Jennifer Kielczewski; Mary Ellen Pease
Journal:  Exp Eye Res       Date:  2006-03-20       Impact factor: 3.467

8.  Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure.

Authors:  Chandrakumar Balaratnasingam; William H Morgan; Louise Bass; Graeme Matich; Stephen J Cringle; Dao-Yi Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

Review 9.  Retinal nerve fiber layer analysis in the diagnosis of glaucoma.

Authors:  Linda M Zangwill; Christopher Bowd
Journal:  Curr Opin Ophthalmol       Date:  2006-04       Impact factor: 3.761

10.  Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma.

Authors:  Gareth R Howell; Richard T Libby; Tatjana C Jakobs; Richard S Smith; F Campbell Phalan; Joseph W Barter; Jessica M Barbay; Jeffrey K Marchant; Nagaraju Mahesh; Vittorio Porciatti; Alan V Whitmore; Richard H Masland; Simon W M John
Journal:  J Cell Biol       Date:  2007-12-24       Impact factor: 10.539

View more
  30 in total

1.  The effects of graded intraocular pressure challenge on the optic nerve head.

Authors:  Nimesh Patel; Faith McAllister; Laura Pardon; Ronald Harwerth
Journal:  Exp Eye Res       Date:  2018-02-01       Impact factor: 3.467

Review 2.  In vivo imaging methods to assess glaucomatous optic neuropathy.

Authors:  Brad Fortune
Journal:  Exp Eye Res       Date:  2015-06-03       Impact factor: 3.467

3.  The non-human primate experimental glaucoma model.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2015-06-09       Impact factor: 3.467

Review 4.  Assessing retinal ganglion cell damage.

Authors:  C A Smith; J R Vianna; B C Chauhan
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

5.  Alterations in molecular pathways in the retina of early experimental glaucoma eyes.

Authors:  Li Cao; Lin Wang; Grant Cull; An Zhou
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-03-20

6.  Influence of the disc-fovea angle on limits of RNFL variability and glaucoma discrimination.

Authors:  Navid Amini; Sara Nowroozizadeh; Nila Cirineo; Sharon Henry; Ted Chang; Tom Chou; Anne L Coleman; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-09       Impact factor: 4.799

7.  Comparing three different modes of electroretinography in experimental glaucoma: diagnostic performance and correlation to structure.

Authors:  Laura Wilsey; Sowjanya Gowrisankaran; Grant Cull; Christy Hardin; Claude F Burgoyne; Brad Fortune
Journal:  Doc Ophthalmol       Date:  2017-02-27       Impact factor: 2.379

8.  Anterior and posterior optic nerve head blood flow in nonhuman primate experimental glaucoma model measured by laser speckle imaging technique and microsphere method.

Authors:  Lin Wang; Grant A Cull; Chelsea Piper; Claude F Burgoyne; Brad Fortune
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-17       Impact factor: 4.799

9.  A Single Intravitreal Injection of Ranibizumab Provides No Neuroprotection in a Nonhuman Primate Model of Moderate-to-Severe Nonarteritic Anterior Ischemic Optic Neuropathy.

Authors:  Neil R Miller; Mary A Johnson; Theresa Nolan; Yan Guo; Steven L Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

10.  A method to estimate the amount of neuroretinal rim tissue in glaucoma: comparison with current methods for measuring rim area.

Authors:  Stuart K Gardiner; Ruojin Ren; Hongli Yang; Brad Fortune; Claude F Burgoyne; Shaban Demirel
Journal:  Am J Ophthalmol       Date:  2013-11-13       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.